Stemtech signs LOI for reverse takeover of Eevia Health and merger with Viago; aims for 85% stake in Eevia

Stemtech Corp

Non-binding LOI for RTO: Stemtech/Viago to acquire Eevia Health (Swedish-listed) by issuing shares; Stemtech to own ~85% of combined entity.
Merger agreement with Seacret Direct/Viago: Stemtech to issue 13M preferred shares (stated value $2.50) convertible into 50% of fully diluted common stock.
Combined entity expects to double Stemtech revenue in 2025 through cost synergies and expanded product portfolio.
Viago/Stemtech operates in 40+ countries with 250,000+ members; Eevia has production facility in Finland.
Closing conditions include audit of Viago, stockholder approvals, and negotiation of definitive agreements; if not closed by June 25, 2025, can terminate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.